BiotechTube
RedShift BioAnalytics

RedShift BioAnalytics

Burlington, United States· Est.
redshiftbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $24.5M

Overview

RedShift BioAnalytics provides critical analytical tools for the biopharmaceutical industry, focusing on the characterization and quantification of therapeutic biomolecules like proteins and RNA. The company's core technology is Microfluidic Modulation Spectroscopy (MMS), a proprietary, label-free spectroscopy method claimed to be 30x more sensitive than traditional FTIR for detecting subtle structural changes. Its product portfolio includes the Aurora TX for biophysical characterization and the HaLCon system for real-time, at-line titer measurement during bioprocessing. RedShiftBio's instruments are positioned to streamline drug development by delivering high-quality data directly in formulation or process buffers, enabling earlier and more informed decisions.

DiagnosticsProteomics

Technology Platform

Microfluidic Modulation Spectroscopy (MMS) - a proprietary, label-free infrared spectroscopy technique for high-sensitivity biomolecular structure analysis, and purpose-built Liquid Chromatography for real-time protein titer measurement.

Funding History

3
Total raised:$24.5M
Series B$15M
Series A$8M
Seed$1.5M

Opportunities

The growing complexity of biotherapeutics (proteins, RNA) and the industry shift towards continuous manufacturing and real-time analytics create strong demand for sensitive, automated characterization and process monitoring tools.
RedShiftBio's platforms are well-positioned to capture market share from slower, less sensitive legacy techniques in both R&D and manufacturing settings.

Risk Factors

Key risks include slow adoption of its novel MMS technology against entrenched competitors, intense competition from large, well-capitalized life science tool companies, and execution challenges in scaling a global hardware business.
Its fortunes are also tied to biopharmaceutical capital expenditure, which can be cyclical.

Competitive Landscape

RedShiftBio competes in the analytical instrumentation space against giants like Agilent, Waters, Thermo Fisher, and Malvern Panalytical. For biophysical characterization, it competes with CD spectrometers, FTIR, and DSC instruments. For titer measurement, it competes with offline HPLC systems and other PAT probes. Its differentiation is based on the claimed superior sensitivity of MMS and the real-time, automated capabilities of HaLCon.

More companies in United States →